Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy

Forty-nine patients undergoing mid-trimester extra-amniotic prostaglandin termination of pregnancy were studied. Twenty patients acted as controls and received the standard hospital regime. Twenty-nine patients received the same regime, but in addition were given a single 200-mg oral dose of the ant...

Full description

Saved in:
Bibliographic Details
Published in:Human reproduction (Oxford) 1989-02, Vol.4 (2), p.202-203
Main Authors: Urquhart, D.R., Bahzad, C., Templeton, A. A.
Format: Article
Language:English
Subjects:
Abortifacient Agents - pharmacology
Abortifacient Agents, Steroidal - pharmacology
Abortion, Legal
Adult
Dinoprostone - pharmacology
Drug Evaluation
Estrenes - pharmacology
extra-amniotic
Female
Humans
Mifepristone
Population
Pregnancy
Progestins - antagonists & inhibitors
prostaglandin
termination of pregnancy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty-nine patients undergoing mid-trimester extra-amniotic prostaglandin termination of pregnancy were studied. Twenty patients acted as controls and received the standard hospital regime. Twenty-nine patients received the same regime, but in addition were given a single 200-mg oral dose of the antiprogesterone, mifepristone (RU 486), 24 h prior to prostaglandin infusion. The dose of prostaglandin required and the induction to abortion interval in the mifepristone-pretreatment group was significantly reduced. Complication rates were similar in both groups. Mifepristone is a safe and useful adjuvant therapy in mid-trimester prostaglandin termination
ISSN:0268-1161
1460-2350
DOI:10.1093/oxfordjournals.humrep.a136872